Clinical trials: Rectal Cancer, completed
Rectal Cancer
Bevacizumab And Combination Chemotherapy in Rectal Cancer Until Surgery
The purpose of this study is to evaluate the efficacy, toxicity and feasibility of FOLFOX/ bevacizumab and FOLFOXIRI/ bevacizumab neoadjuvant therapy in poor prognosis rectal cancer as defined by MRI.
- Trial name
- BACCHUS (NCT01650428)
- Testing
- Bevacizumab, Irinotecan, Oxaliplatin
- Where
- 11 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- University College, London
Adult Giant Cell Glioblastoma, Adult Glioblastoma
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with glioblastoma multiforme…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Male Breast Cancer
- Trial name
- NCT01806675
- Testing
- 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sanjiv Sam Gambhir
Pancreatic Cancer, Colorectal Cancer
TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors
This is a Phase 1 multi-center study to assess the safety and efficacy of TGR-1202 as a single agent or in combination with nab-paclitaxel + gemcitabine or with FOLFOX in patients with select relapsed or refractory solid tumors.
- Conditions
- Pancreatic Cancer, Colorectal Cancer, Rectal Cancer, Gastric Cancer
- Trial name
- NCT02574663
- Testing
- TGR-1202, nab-paclitaxel + gemcitabine, Oxaliplatin + Folinic acid + Fluorouracil
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- TG Therapeutics, Inc.
Anastomotic Leak
Anastomotic Leakage After Anterior Resection for Rectal Cancer - Predictive Biomarkers and Rectal Blood Flow
The purpose of this study is to determine whether reduced rectal blood flow is associated with the extent of surgery when performing an operation to remove rectal cancer.
- Trial name
- NCT02401100
- Where
- Sweden
- Volunteers
- 36 people
- Sponsor
- Umeå University
Rectal Neoplasm Carcinoma in Situ Adenocarcinoma
Metformin With Neoadjuvant Chemoradiation to Improve Pathologic Responses in Rectal Cancer
This study is a phase II, single arm, controlled, open label internal pilot.
- Trial name
- NCT03053544
- Testing
- Metformin
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- Sunnybrook Health Sciences Centre
Rectal Cancer, Sigmoid Cancer
A Study of Perfusion of Colorectal Anastomosis Using FLuorescence AnGiography (FLAG-trial)
This is a randomized, controlled, parallel study to determine the difference in post-operative anastomotic leak rate of colorectal anastomosis where colon and rectal tissue perfusion is evaluated using fluorescence angiography…
- Trial name
- FLAG (NCT03390517)
- Testing
- Fluorescence angiography with indocianyne green
- Where
- Russia
- Volunteers
- 377 people, healthy volunteers welcome
- Sponsor
- State Scientific Centre of Coloproctology, Russian Federation
Rectal Cancer
Radiographic Validation of the Inferior Mesenteric Artery Tie Level in Rectal Cancer Surgery
The inferior mesenteric artery is the feeding vessel for tumours in the rectum. When performing surgery for these tumours, the surgeon can cut the vessel close to the aorta or after the vessel bifurcates to the superior rectal…
- Trial name
- RAVAL (NCT03875612)
- Where
- 2 sites in Sweden
- Volunteers
- 98 people
- Sponsor
- Umeå University
Colon Mucinous Adenocarcinoma, Colon Signet Ring Cell Adenocarcinoma
Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
This phase II trial studies how well v-akt murine thymoma viral oncogene homolog 1 (Akt) inhibitor MK2206 works in treating patients with previously treated colon or rectal cancer that has spread from the primary site to other…
- Conditions
- Colon Mucinous Adenocarcinoma, Colon Signet Ring Cell Adenocarcinoma, Rectal Mucinous Adenocarcinoma, Rectal Signet Ring Cell Adenocarcinoma
- Trial name
- NCT01802320
- Testing
- Akt Inhibitor MK2206, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
Health Behaviors in Patients Who Have Finished Treatment for Stage I, Stage II, or Stage III Colorectal Cancer
RATIONALE: Gathering information over time from patients who have finished treatment for colorectal cancer may help doctors predict which cancer survivors will improve their physical activity and diet.
- Trial name
- NCT00966667
- Where
- 14 sites in United States
- Volunteers
- 222 people
- Sponsor
- Rutgers, The State University of New Jersey
Rectal Cancer
BioXmark, Rectal Feasibility Trial
To test the feasibility and accuracy of BioXmark fiducial markers for image guided radiotherapy (IGRT) based rectal tumor boosting in 20 patients referred for long course chemo-radiotherapy of the locally advanced rectal cancer.
- Trial name
- NCT03265418
- Testing
- BioXmark liquid fiducial markers, Imaging, surgery or wait-and-see
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Maastricht Radiation Oncology
Colon Rectal Cancer Adenocarcinoma
FAZA PET as Biomarker for Hypoxia in Rectal Cancer
Colorectal cancer (CRC) is one of the leading causes of cancer mortality in Canada. Rectal cancers are now known to be hypoxic which is a negative prognostic factor and predictive of metastatic spread and poor responsiveness to…
- Trial name
- NCT02624115
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- University Health Network, Toronto
Colorectal Cancer, Metastatic Cancer
Study of Colon GVAX and Cyclophosphamide in Patients With Metastatic Colorectal Cancer
The primary objective of this study is to evaluate the safety and feasibility of vaccination with two irradiated allogeneic colorectal carcinoma cells administered with a GM-CSF producing bystander cell line in sequence with an…
- Trial name
- NCT00656123
- Testing
- Colon GVAX, cyclophosphamide
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Colon Cancer, Rectal Cancer
A Study of Ramucirumab or Icrucumab in Colorectal Cancer
The purpose of this study is to determine if participants with metastatic colorectal cancer live longer without their cancer progressing when treated with standard chemotherapy, standard chemotherapy plus ramucirumab, or standard…
- Trial name
- NCT01111604
- Testing
- Ramucirumab, Icrucumab, mFOLFOX-6
- Where
- 17 sites in United States, Canada
- Volunteers
- 158 people
- Sponsor
- Eli Lilly and Company
Colon Cancer, Rectum Cancer
Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas
This study evaluates the safety and performance of SGM-101, a Carcinoembryonic Antigen (CEA)-specific chimeric antibody conjugated with a NIR emitting fluorochrome, for the visualization of CEA-expressing cancers during surgery.
- Conditions
- Colon Cancer, Rectum Cancer, Pancreas Cancer, Metastatic Colorectal Cancer
- Trial name
- NCT02973672
- Testing
- SGM-101
- Where
- 3 sites in Netherlands
- Volunteers
- 75 people
- Sponsor
- Surgimab
Locally Advanced Rectal Cancer
Neoadjuvant Bevacizumab, Capecitabine and Radiation Therapy With or Without Oxaliplatin Locally Advanced Rectal Cancer
Phase II clinical trial, open-label, randomized, two arms, multicentre (possibly multinational). Academic, investigator initiated.
- Trial name
- AXEBEAM (NCT00828672)
- Testing
- Oxaliplatin, Bevacizumab, Capecitabine
- Where
- 9 sites in Belgium
- Volunteers
- 84 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Neoadjuvant Chemoradiotherapy, Rectal Tumor
Outcomes of Resection at Different Times Between the End of Neoadjuvant Treatment and Surgery
Neoadjuvant radio-chemotherapy (NRCT) represents a milestone in the treatment of selected rectal tumours. Ideal time interval between the end of NRCT and surgery is still debated; a 6-8 weeks time interval is considered optimal…
- Conditions
- Neoadjuvant Chemoradiotherapy, Rectal Tumor, Surgery, Surgery--Complications
- Trial name
- NCT04013347
- Testing
- Rectal Resection
- Volunteers
- 167 people, healthy volunteers welcome
- Sponsor
- Campus Bio-Medico University
Colorectal Cancer
Capecitabine and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004187
- Testing
- capecitabine, oxaliplatin
- Where
- Switzerland
- Sponsor
- Swiss Cancer Institute
Colorectal Cancer
Rectal Reconstruction in Treating Patients Who Are Undergoing Surgery for Rectal Cancer
RATIONALE: Rectal reconstruction after surgery to treat rectal cancer may help patients keep some of their bowel function. It is not yet known which method of rectal reconstruction is most effective after surgery.
- Trial name
- NCT00238381
- Testing
- 5 cm colon-J-pouch, side-to-end anastomosis, straight coloanal anastomosis
- Where
- 18 sites in Germany, Switzerland
- Volunteers
- 336 people
- Sponsor
- Swiss Cancer Institute
Cancer
E-MOSAIC Electronic Tool to Monitor Symptoms
RATIONALE: A hand held electronic tool used to monitor symptoms and assess quality of life may improve communication between patients and their doctors and improve the ability to plan treatment for patients with advanced cancer…
- Trial name
- NCT00477919
- Where
- 7 sites in Switzerland
- Volunteers
- 264 people
- Sponsor
- Swiss Cancer Institute
Colorectal Cancer
External-Beam Radiation Therapy, Capecitabine, and Sorafenib in Treating Patients With Locally Advanced Rectal Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NCT00869570
- Testing
- capecitabine, sorafenib tosylate, radiation therapy
- Where
- 18 sites in Hungary, Switzerland
- Volunteers
- 54 people
- Sponsor
- Swiss Cancer Institute